68Ga-PSMA-11 PET as a gatekeeper for the treatment of metastatic prostate cancer with 223Ra: Proof of concept

Journal of Nuclear Medicine

Volumn 58, Issue 3, 2017, Pages 438-444

  Ahmadzadehfar, Hojjat ^a   Azgomi, Kambiz ^a   Hauser, Stefan ^a   Wei, Xiao ^a   Yordanova, Anna ^a   Gaertner, Florian C ^a   Kürpig, Stefan ^a   Strunk, Holger ^a   Essler, Markus ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

223Ra; Bone metastases; Bone scan; PET; Prostate cancer; PSMA; Radionuclide therapy

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN 11 GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN LU 177; RADIUM CHLORIDE RA 223; TRACER; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ORGANOMETALLIC COMPOUND; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; TREATMENT PLANNING; VERY ELDERLY; BONE NEOPLASMS; DIAGNOSTIC IMAGING; IMAGE GUIDED RADIOTHERAPY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, IMAGE-GUIDED; RADIUM; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85014814288     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.178533     Document Type: Article

References (41)

1. Liepe K, Kotzerke J. Internal radiotherapy of painful bone metastases. Methods. 2011;55:258-270
2. Hoskin P, Sartor O, O'Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397-1406
3. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587-594
4. Parker C, Sartor O. Radium-223 in prostate cancer. N Engl JMed. 2013;369:1659-1660
5. Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738-746
6. Cookson MS, Lowrance WT, Murad MH, Kibel AS. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015;193:491-499
7. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436-3448
8. Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v69-v77
9. Mikah P, Krabbe LM, Eminaga O, et al. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer. 2016;16:214
10. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197
11. Mahammedi H, Planchat E, Pouget M, et al. The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study. Oncology. 2016;90:69-78
12. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159
13. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223
14. Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective. Urology. 2015;85:717-724
15. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; 41:11-20
16. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495
17. Rahbar K, Weckesser M, Huss S, et al. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016; 57:563-567
18. Schlenkhoff CD, Gaertner F, Essler M, Hauser S, Ahmadzadehfar H. 68Ga-labeled anti-prostate-specific membrane antigen peptide as marker for androgen deprivation therapy response in prostate cancer. Clin Nucl Med. 2016;41:423-425
19. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674
20. Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114
21. Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrateresistant metastatic prostate cancer. Oncotarget. 2016;7:12477-12488
22. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castrationresistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152-160
23. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154
24. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castrationresistant prostate cancer. J Natl Cancer Inst. 2012;104:1107-1109
25. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520
26. Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016;43:8-20
27. Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006-1013
28. Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41:522-528
29. Rahbar K, Schmidt M, Heinzel A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57:1334-1338
30. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016;57:1170-1176
31. Schlenkhoff CD, Gaertner F, Essler M, Schmidt M, Ahmadzadehfar H. Positive influence of 177Lu PSMA-617 therapy on bone marrow depression caused by metastatic prostate cancer. Clin Nucl Med. 2016;41:478-480
32. Schlenkhoff CD, Knupfer E, Essler M, Ahmadzadehfar H.Metastatic prostate cancer with restored hormone-response after radioligand therapy with 177Lu-PSMA-617. Clin Nucl Med. 2016;41:572-573
33. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14:19-30
34. Bortot DC, Amorim BJ, Oki GC, et al. 18F-fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730-1736
35. Florimonte L, Dellavedova L, Maffioli LS. Radium-223 dichloride in clinical practice: a review. Eur J Nucl Med Mol Imaging. 2016;43:1896-1909
36. Etchebehere EC, Araujo JC, Milton DR, et al. Skeletal tumor burden on baseline 18F-fluoride PET/CT predicts bone marrow failure after 223Ra therapy. Clin Nucl Med. 2016;41:268-273
37. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56:1177-1184
38. Miederer M, Thomas C, Beck J, et al. Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden. Nuklearmedizin. 2015;54:197-203
39. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209
40. Afshar-Oromieh A, Haberkorn U, EderM, EisenhutM, Zechmann CM. [68Ga]galliumlabelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085-1086
41. Santoni M, Scarpelli M, Mazzucchelli R, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J Biol Regul Homeost Agents. 2014;28:555-563.